<DOC>
	<DOCNO>NCT00351130</DOCNO>
	<brief_summary>Essential hypertension widespread disease affect one every three adult industrialized world . It contribute cardiovascular disease development , major well establish risk factor . A patient non compliant drug therapy recognize one primary reason inadequate blood pressure control .</brief_summary>
	<brief_title>Effectiveness Valsartan Based v Amlodipine Based Treatment Strategy na√Øve Patients With Stage 1 Stage 2 Hypertension Patients Uncontrolled Current Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion MSSBP &gt; 140 mm Hg , and/or MSDBP &gt; 90 mm Hg currently treat either valsartan 320 mg/ HCTZ 25 mg amlodipine 10 mg/HCTZ 25 mg end core study Exclusion criterion Premature discontinuation core study failure comply core study protocol Any patient investigator decides participate extension Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertension ,</keyword>
	<keyword>stage 1 hypertension ,</keyword>
	<keyword>stage 2 hypertension ,</keyword>
	<keyword>valsartan ,</keyword>
	<keyword>amlodipine ,</keyword>
</DOC>